Drugs · acquisition-cost intelligence
CellCept
mycophenolate mofetil· ingredient mycophenolate mofetil· MYCOPHENOLATE MOFETIL 200 mg/mL; MYCOPHENOLATE MOFETIL 250 mg/1; MYCOPHENOLATE MOFETIL 500 mg/1; MYCOPHENOLATE MOFETIL HYDROCHLORIDE 500 mg/20mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.13981
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other mycophenolate mofetil products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| mycophenolate mofetil | $0.27378 | +$0.13400 |
| MYHIBBIN | $0.97477 | +$0.83500 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 100% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.